Company Update (NYSE:AGN): Allergan Files Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator

[PR Newswire] – DUBLIN, July 18, 2016 /PRNewswire/ — Allergan plc (AGN) announced today that it has filed with the U.S. Food and Drug Administration (FDA) the de novo application for the Oculeve Intranasal Tear Neurostimulator device. According to the FDA, this process provides a pathway for medical devices for which general and/or special controls provide a reasonable assurance of safety and effectiveness, but for which there is no legally marketed predicate device. This handheld stimulator was investigated for temporarily increasing tear production upon activation in patients with dry eye disease due to decreased tear production. Read more on this. , currently valued at $recting to http://finance.ya, ended trading yesterday at $. Today’s price range has been between $ per share and has traded between $ over the past 12 months. AGN shares are currently priced at x this year’s forecasted earnings, which makes them relatively inexpensive compared to the industry’s x forward p/e ratio. Consensus earnings for the current quarter by the 0 sell-side analysts covering the stock is an estimate of $ per share, which would be $0.00 worse than the year-ago quarter and a $0.00 sequential decrease. Investors should also note that the full-year EPS estimate of $ is a $0.00 setback when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $0.00 . If realized, that would be a 0.00% decrease over the year-ago quarter. In terms of ratings, d AGN from to (/fi). Previously, d AGN from to . Given all the information above, we should disclose to readers that the average price target is $, which is 0.00% below than it opened this morning. See more in (NYSE:AGN) Similar Articles: Stock Update (NYSE:AGN): Teva says Allergan deal to close ‘any time’, expects U.S. antitrust clearance Stock Update: Allergan Inc (NYSE:AGN) – Allergan Announces FDA Approval of Supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and avibactam) Stock Update (NYSE:AGN): Allergan Announces FDA Approval of ACZONE® (dapsone) Gel, 7.5% for Treatment of Acne Vulgaris